Published in Onco Targets Ther on October 21, 2016
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Cancer statistics in China, 2015. CA Cancer J Clin (2016) 12.92
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
TLR signaling. Semin Immunol (2007) 8.16
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med (2007) 6.52
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta (2010) 2.08
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol (2015) 1.74
TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev (2008) 1.52
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res (2014) 1.52
NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett (2006) 1.49
Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr Opin Microbiol (2002) 1.43
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer (2015) 1.32
Nuclear factor-kappaB and manganese superoxide dismutase mediate adaptive radioresistance in low-dose irradiated mouse skin epithelial cells. Cancer Res (2007) 1.27
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure (2015) 1.27
Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer (2005) 1.18
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep (2015) 1.18
NFκB inhibitors induce cell death in glioblastomas. Biochem Pharmacol (2010) 1.17
NF-kappaB in cancer--a friend turned foe. Drug Resist Updat (2004) 1.08
Radioimmunotherapy of human tumours. Nat Rev Cancer (2015) 1.07
CD300a/c regulate type I interferon and TNF-alpha secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands. Blood (2008) 1.00
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. Cancer Res (2015) 0.98
Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J Cell Physiol (2012) 0.98
Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. Cancer Lett (2015) 0.96
Inhibition of expression of anti-apoptotic protein Bcl-2 and induction of cell death in radioresistant human prostate adenocarcinoma cell line (PC-3) by methyl jasmonate. Cancer Lett (2008) 0.89
CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-κB activation and NO production. Tumour Biol (2012) 0.89
Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res (2014) 0.88
NF-κB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. PLoS One (2013) 0.87
Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells. Clin Cancer Res (2006) 0.87
PD-L1 expression in small cell lung cancer. Eur J Cancer (2015) 0.87
Radiotherapy and immune checkpoint blockade: potential interactions and future directions. Trends Mol Med (2015) 0.84
CpG-ODN 7909 increases radiation sensitivity of radiation-resistant human lung adenocarcinoma cell line by overexpression of Toll-like receptor 9. Cancer Biother Radiopharm (2013) 0.83
Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. Ann Oncol (2015) 0.81
Radiotherapy complements immune checkpoint blockade. Cancer Cell (2015) 0.79
Radiotherapy diagnostic biomarkers in radioresistant human H460 lung cancer stem-like cells. Cancer Biol Ther (2016) 0.77
CpG oligodeoxyribonucleotide 7909 enhances radiosensitivity via downregulating Oct-4 expression in radioresistant lung cancer cells. Onco Targets Ther (2015) 0.76
CpG Oligodeoxynucleotide1826 combined with radioresistant cancer cell vaccine confers significant antitumor effects. Neoplasma (2015) 0.76